Skip to main content

Table 3 Subject profiles, representing 5th percentile (low), midpoint and 95th percentile (high) CV risk

From: Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials

 

Low CV risk

Midpoint CV risk

High CV risk

CV risk score: –2.53

CV risk score: –1.39

CV risk score: –0.25

NNT: 380

NNT: 159

NNT: 117

Subject profile

A

B

C

D

E

F

Hazard ratio (semaglutide vs comparators)

0.45

0.45

0.62

0.62

0.84

0.84

Age, years

48

46

66

67

64

71

HbA1c, %

8.6

7.0

7.2

10.3

9.6

9.4

Smoking status, current/previous/never

Never

Never

Previous

Never

Previous

Never

LDL-C, mmol/L

3.3

3.3

3.2

3.9

4.5

5.2

Pulse rate, bpm

76

80

76

67

66

88

Systolic BP, mmHg

119

138

137

163

133

180

Prior ischemic heart disease, yes/no

No

No

No

No

No

Yes

Prior MI, yes/no

No

No

No

No

No

No

Prior stroke, yes/no

No

No

No

No

Yes

No

HF, NYHA class

No HF

No HF

No HF

No HF

Othera

II

Insulin use, yes/no

No

No

No

No

Yes

No

eGFR, ml/min/1.73 m2

117.7

116.2

91.7

94.1

88.9

66.9

  1. Examples of real subject profiles were chosen at the 5th, midpoint and 95th percentiles of CV risk score distribution. The factors listed are those that were identified, based on data from LEADER, as having a significant effect on CV risk (no other factors were identified as important)
  2. aOther: subject either had no HF or Class I HF
  3. BP blood pressure, bpm beats per minute, CV cardiovascular, eGFR estimated glomerular filtration rate, HbA1c glycated hemoglobin, HF heart failure, LDL-C low-density lipoprotein cholesterol, MI myocardial infarction, NNT numbers needed to treat, NYHA New York Heart Association